Meldungen sortieren nach Relevanz Meldungsdatum
|
Roches xCELLigence Cardio Instrument misst Schlagrhythmus und proarrhythmische Wirkungen von Substanzen in aus Stammzellen erzeugten Kardiomyozyten
, Forschung und Entwicklung, Roche Diagnostics GmbH
Wissenschaftler des University Medical Center Utrecht in den Niederlanden und der Abteilung Bioscience der Forschungsabteilung von Astra Zeneca in Mölndal (Schweden)...
|
|
Roche's xCELLigence Cardio Instrument Used to Detect Beating Rhythm and Proarrhythmic Effects of Compounds in Stem Cell-Derived Cardiomyocytes
, Forschung und Entwicklung, Roche Diagnostics GmbH
In an effort to improve preclinical cardiotoxicity assays, reduce drug testing attrition rates, and ensure drug safety, collaborating scientists at the University...
|
|
Roche's xCELLigence System Monitors Beating Periodicity of Stem Cell Derived Cardiomyocytes in Preclinical Safety Assessment
, Forschung und Entwicklung, Roche Diagnostics GmbH
Cardiac toxicity is a major concern in drug development and it is imperative that clinical candidates are thoroughly tested for adverse effects earlier in the drug...
|
|
Roche's xCELLigence RTCA Cardio Instrument Used to Estimate the Risk of Drug-induced Proarrhythmia in Human Induced Pluripotent Stem Cell Derived Cardiomyocytes
, Biotechnik, Roche Diagnostics GmbH
Cardiotoxicity, which results when drugs adversely affect the heart, explains why roughly one third of new pharmaceuticals are withdrawn from the market and why...
|
|
Roche Diagnostics supports European Union's DETECTIVE Project to reduce Animal Testing
, Biotechnik, Roche Diagnostics GmbH
The xCELLigence RTCA System of Roche (SIX: RO, ROG; OTCQX: RHHBY) is being used in the European Union's DETECTIVE ("Detection of endpoints and biomarkers for repeated...
|
|
AgenoLAB Broadens Service Offering for Drug Development with Roche's RTCA Cardio Instrument
, Medizintechnik, Roche Diagnostics GmbH
AgenoLAB, the Stuttgart-based service provider, is the first company in Germany to expand its service offering with the latest cell analysis technology from Roche...
|
|
Roche's new RTCA Cardio Instrument for label-free functional cardiomyocyte toxicity testing
, Biotechnik, Roche Diagnostics GmbH
Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that it had launched the RTCA Cardio Instrument, the latest member of the xCELLigence product family. The RTCA...
|
|
Cellular Dynamics International, ACEA Biosciences, and Roche Applied Sciences Cooperate to Evaluate iCell Cardiomyocytes on the xCELLigence System
, Biotechnik, Roche Diagnostics GmbH
Cellular Dynamics International (CDI) announced today their partnership with ACEA Biosciences to bring early and accurate prediction of potential cardiotoxic side...
|
Nanion and Axiogenesis present parallel patch clamp recordings of action potentials from Cor.At cardiomyocytes
, Forschung und Entwicklung, Nanion Technologies GmbH
Stem cell derived cardiomyocytes have tremendous potential for cardiac safety testing of drug candidates. By offering an authentic cellular environment they are...
|
|
Roche joins forces to innovate toxicity testing and to reduce animal experimentation
, Forschung und Entwicklung, Roche Diagnostics GmbH
Today, Roche opened the Joint Science & Technology Laboratory in Basel, where Roche Pharma scientists are using the innovative xCELLigence real-time Cell Analyzer...
